Massachusetts is currently home to 3215 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT
NCT06910956
Recruiting
The goal of this clinical trial is to evaluate whether an AI tool that alerts providers to patients at high 6-year risk of lung cancer based on their chest x-ray images will improve lung cancer screening CT participation. The main question it aims to answer is: Does the AI tool improve lung cancer screening CT participation at 6 months after the baseline outpatient visit The intervention is an alert to the provider to discuss lung cancer screening CT eligibility, for patients considered at high... Read More
Gender:
ALL
Ages:
Between 50 years and 77 years
Trial Updated:
06/05/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Lung Cancer, Health Screening, Early Cancer Detection, Deep Learning
Register for Updates
Therapy Dog Visits for Patients Hospitalized With Traumatic Injuries
NCT06812247
Recruiting
Animal assisted therapy (AAT) with dogs has been shown to be beneficial for a wide range of patients with both acute and chronic illnesses, including spinal cord injuries, heart failure, myocardial infarctions, strokes, cancer, post-traumatic stress disorder, and depression. Studies have also demonstrated that even in healthy adults, the presence of dogs is associated with physiologic changes such as increased pain threshold, decreased blood pressure, and decreased heart rate. However, few studi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Boston Medical Center, Trauma Inpatient Service, Boston, Massachusetts
Conditions: Trauma Injury, Depression, Anxiety, Anger, Pain
Register for Updates
Semaglutide for Helping Opioid Recovery
NCT06639464
Recruiting
The is a pilot, 12-week, double-blind, placebo-controlled, randomized trial of individuals with opioid use disorder (OUD) newly initiating buprenorphine to receive either weekly injections of semaglutide (n=23) or matching placebo (n=23). The primary aim is to determine the effects of semaglutide on cue-reactivity among individuals with OUD. The secondary aim is to assess the preliminary efficacy, safety, and tolerability of semaglutide for OUD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Opioid Use Disorder
Register for Updates
Get Social Media and Risk-Reduction Training
NCT06618586
Recruiting
This study examines the implementation of the TodaysBaby™ mobile safe sleep intervention program in US hospitals. The main aims of this study are to examine: 1) differences in program penetration and the equity of penetration according to income and race/ethnicity; 2) differences in feasibility, acceptability, sustainability and fidelity top the intervention; and 3) the effectiveness of the intervention.
Gender:
FEMALE
Ages:
All
Trial Updated:
06/05/2025
Locations: Boston University, Boston, Massachusetts
Conditions: Infant Death, Sudden Infant Death
Register for Updates
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
NCT06373731
Recruiting
The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
06/05/2025
Locations: Ophthalmic Consultants of Boston, Boston, Massachusetts
Conditions: Age Related Macular Degeneration (ARMD)
Register for Updates
PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency
NCT06302439
Recruiting
The purpose of this prospective registry is to characterize the natural history of ectonucleotide pyrophosphatase/phosphodiesterase1(ENPP1) Deficiency and the infantile-onset form of adenosine triphosphate (ATP) binding cassette transporter protein subfamily C member 6 (ABCC6) Deficiency longitudinally. The registry will prospectively gather information about the genetic, biochemical, physiological, anatomic, radiographic, and functional manifestations (including patient reported outcomes \[PROs... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/05/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: ATP-Binding Cassette Subfamily C Member 6 Deficiency, Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency
Register for Updates
The STOP-MED CTRCD Trial
NCT06183437
Recruiting
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients. When this occurs, heart failure medications are started to protect the heart from progressing to heart failure. With early detection and treatment, heart function recovers to normal in \>80% of patients. Unfortunately, heart failure medications are associated with an undesirable... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity, Cancer
Register for Updates
Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (SA-AKI)
NCT05996835
Recruiting
The purpose of this Ph2b study is to characterize the dose-response relationship and to evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis-associated acute kidney injury (SA-AKI).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/05/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Acute Kidney Injury Due to Sepsis
Register for Updates
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT05987332
Recruiting
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Metastatic Uveal Melanoma
Register for Updates
Assessment of Combined CCM and ICD Device in HFrEF
NCT05855135
Recruiting
The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced le... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Implantable Defibrillator User, CCM Therapy, Non-ischemic Cardiomyopathy, Ischemic Cardiomyopathy, Sudden Cardiac Arrest, Arrhythmias, Cardiac, Ventricular Tachycardia, Ventricular Fibrillation
Register for Updates
Safety and Efficacy of TSHA-102 in Adolescent and Adult Females With Rett Syndrome (REVEAL Adult Study)
NCT05606614
Recruiting
The REVEAL Adult Study is a multi-center, Phase 1/2 open-label, dose-escalation study of TSHA-102, an investigational gene therapy, in adult females with Rett syndrome. The safety, tolerability, and preliminary efficacy of two dose levels will be evaluated. The study duration is estimated to be up to 63 months.
Gender:
FEMALE
Ages:
12 years and above
Trial Updated:
06/05/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Rett Syndrome
Register for Updates
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT05600777
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/05/2025
Locations: GSK Investigational Site, Methuen, Massachusetts
Conditions: Refractory Chronic Cough, Cough
Register for Updates